Oncoinvent ASA: Grant of share options – mandatory notification of trade

Oncoinvent granted a replacement option programme (6,355,096 options, 4,451,133 to primary insiders) following its merger adjustment and issued 25,770,000 new share options (5.4% of fully diluted shares), bringing total options outstanding to 32,125,096 (6.7% of fully diluted). The new grants carry a NOK 0.50 strike (VWAP prior day, limited to nominal value), normally vest over four years and expire after seven years; 15,500,000 of the new options were allocated to primary insiders (including CEO Øystein Soug: 5,000,000). The board frames the programme as value‑neutral post‑merger and intended to retain staff, while the issuance represents modest dilution for shareholders.

Analysis

Market structure: The grant creates a material equity overhang — 32.1M options = 6.7% fully diluted — concentrated in insiders (≈15.5M new options). That increases potential supply into the market when options vest/exercise and/or insiders liquidate, which will cap near-term upside and increase volatility until major clinical catalysts materialize (next 6–18 months). Small-cap radiopharma peers will not see the same immediate dilution, so relative flows may favor better-capitalized names.

Risk assessment: Tail risks include a negative Phase 2 readout or regulatory safety concern for Radspherin (alpha-emitter toxicity) that could erase valuation (low-probability, high-impact) and manufacturing/regulatory setbacks given in‑house small-scale production. Immediate risk (days–weeks) is insider selling/market perception; short-term (3–6 months) is dilution/volatility from option overhang; long-term (12–24 months) depends on Phase 2 efficacy/safety and commercial scaling.

Trade implications: Direct plays should size long exposure to ONCOIN conservatively (1–2% NAV) and hedge tail risk; consider relative-value pair trades vs. larger, non-diluted radiopharma/oncology names (long BGBIO or NVS, short ONCOIN) to isolate idiosyncratic dilution. Options strategies favor protective puts (9–12 month, ~30–40% OTM) or covered-call overlays if initiating a small long, while avoiding uncovered long gamma until clinical readouts.

Contrarian angles: The board framing (value‑neutral replacement, low strike NOK0.50) signals management wants retention not a capital raise — this can be constructive if execution on Phase 2 reduces absolute option overhang value. If readouts are strongly positive within 12 months, the option pool becomes accretive to retention and upside capture; downside is insider liquidation once vesting cliffs clear. Monitor insider transaction filings and trial milestone dates as binary de-riskers.

Key Decisions for Investors

• If you hold ONCOIN (OSE:ONCOIN), trim to <=2% portfolio weight immediately to reduce concentration risk and buy a 9–12 month protective put ~30–40% below spot (or equivalent cash collar) to cap downside from safety or dilution shocks.
• Establish a pair trade: short ONCOIN notional equal to a 1–2% NAV long in a larger, better-capitalized oncology/radiopharma name (example long BGBIO OSE:BGBIO or large-cap NVS) to capture idiosyncratic dilution/insider-selling risk over a 3–12 month horizon.
• For opportunistic long exposure, buy shares only after at least one clinical milestone clears (interim safety/efficacy) or if insider filings show no material sell-down within 60 days; until then, prefer 3–6 month covered calls at ~10–20% above purchase price to monetize time decay.
• Monitor these triggers in the next 30–90 days and act: insider sales >1% free float, formal Phase 2 interim data release, or regulator comments on radium-224 — any of these should prompt reweighting by +/-50% from the positions above.